Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-04-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173558472310784 |
|---|---|
| author | Xiaoshuai Zhang Yunfan Yang Bingcheng Liu Xin Du Xiaodong Wang Huanling Zhu Lu Yu Zongru Li Shasha Zhao Linhua Yang Yanping Ma Li Meng Yanqing Zhang Guohui Li Lijie Yang Baohong Wang Xuehong Ran Jian Huang Na Gao Qin Wen Yan Wen Yuxia Zhao Yu Zhu Yanqiu Han Zhenfang Liu Xin Du Jianyu Weng Robert Peter Gale Li Zhou Yanli Zhang Qian Jiang |
| author_facet | Xiaoshuai Zhang Yunfan Yang Bingcheng Liu Xin Du Xiaodong Wang Huanling Zhu Lu Yu Zongru Li Shasha Zhao Linhua Yang Yanping Ma Li Meng Yanqing Zhang Guohui Li Lijie Yang Baohong Wang Xuehong Ran Jian Huang Na Gao Qin Wen Yan Wen Yuxia Zhao Yu Zhu Yanqiu Han Zhenfang Liu Xin Du Jianyu Weng Robert Peter Gale Li Zhou Yanli Zhang Qian Jiang |
| author_sort | Xiaoshuai Zhang |
| collection | DOAJ |
| description |
Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N = 216) and a reduced dose of 30 mg QOD (N = 66) in subjects failing other tyrosine kinase-inhibitors (TKIs). The cohorts were similar in baseline co-variates and adjusted for by propensity score matching (PSM). There were no significant differences in cytogenetic and molecular responses, as well as outcomes between the 2 dose cohorts. However, the proportion of subjects receiving the original olverembatinib dose at the last follow-up was significantly higher in the 30 mg cohort (64% [95%Confidence Interval [CI], 53, 75%] versus 44% [37,51%]; p = 0.004). Also, the proportion of subjects receiving a reduced dose or permanently discontinuing because of adverse event was significantly lower in the 30 mg cohort (21% [9, 33%] versus 41% [34, 48%]; p = 0.003). In summary, olverembatinib, 30 mg QOD starting dose is as effective as a 40 mg starting dose but better tolerated in persons with chronic phase CML failing other TKIs.
|
| format | Article |
| id | doaj-art-8632c028452c403696b2a70c73b99e0d |
| institution | OA Journals |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-8632c028452c403696b2a70c73b99e0d2025-08-20T02:19:50ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-04-01999110.3324/haematol.2024.287116Optimizing olverembatinib dose in chronic phase chronic myeloid leukemiaXiaoshuai Zhang0Yunfan Yang1Bingcheng Liu2Xin Du3Xiaodong Wang4Huanling Zhu5Lu Yu6Zongru Li7Shasha Zhao8Linhua Yang9Yanping Ma10Li Meng11Yanqing Zhang12Guohui Li13Lijie Yang14Baohong Wang15Xuehong Ran16Jian Huang17Na Gao18Qin Wen19Yan Wen20Yuxia Zhao21Yu Zhu22Yanqiu Han23Zhenfang Liu24Xin Du25Jianyu Weng26Robert Peter Gale27Li Zhou28Yanli Zhang29Qian Jiang30Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, BeijingDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, SichuanNational Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, TianjingDepartment of Hematology, The Second People’s Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, ShenzhenDepartment of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People’s Hospital, SichuanDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, SichuanPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, BeijingPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, BeijingPeking University People’s Hospital, QingdaoDepartment of Hematology, Second Hospital of Shanxi Medical University, TaiyuanDepartment of Hematology, Second Hospital of Shanxi Medical University, TaiyuanDepartment of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, WuhanDepartment of Hematology, Shenzhen Hospital of Southern Medical University, ShenzhenDepartment of Hematology, Xi’an international medical center hospital, Xi’anDepartment of Hematology, Xi’an international medical center hospital, Xi’anDepartment of Hematology, Weifang People's Hospital, WeifangDepartment of Hematology, Weifang People's Hospital, WeifangDepartment of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, ZhejiangDepartment of Hematology, Binzhou Medical University Hospital, BinzhouMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, ChongqingDepartment of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, KunmingDepartment of Hematology, The People's Hospital of Xing'an League, Ulanhot, Inner Mongolia Autonomous RegionDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, NanjingDepartment of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Inner MongoliaDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, GuangxiDepartment of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, GuangzhouDepartment of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, GuangzhouDepartment of Immunology and Inflammation, Centre for Hematology, Imperial College London, LondonShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, ShanghaiDepartment of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, HenanPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking University People’s Hospital, Qingdao Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N = 216) and a reduced dose of 30 mg QOD (N = 66) in subjects failing other tyrosine kinase-inhibitors (TKIs). The cohorts were similar in baseline co-variates and adjusted for by propensity score matching (PSM). There were no significant differences in cytogenetic and molecular responses, as well as outcomes between the 2 dose cohorts. However, the proportion of subjects receiving the original olverembatinib dose at the last follow-up was significantly higher in the 30 mg cohort (64% [95%Confidence Interval [CI], 53, 75%] versus 44% [37,51%]; p = 0.004). Also, the proportion of subjects receiving a reduced dose or permanently discontinuing because of adverse event was significantly lower in the 30 mg cohort (21% [9, 33%] versus 41% [34, 48%]; p = 0.003). In summary, olverembatinib, 30 mg QOD starting dose is as effective as a 40 mg starting dose but better tolerated in persons with chronic phase CML failing other TKIs. https://haematologica.org/article/view/12047 |
| spellingShingle | Xiaoshuai Zhang Yunfan Yang Bingcheng Liu Xin Du Xiaodong Wang Huanling Zhu Lu Yu Zongru Li Shasha Zhao Linhua Yang Yanping Ma Li Meng Yanqing Zhang Guohui Li Lijie Yang Baohong Wang Xuehong Ran Jian Huang Na Gao Qin Wen Yan Wen Yuxia Zhao Yu Zhu Yanqiu Han Zhenfang Liu Xin Du Jianyu Weng Robert Peter Gale Li Zhou Yanli Zhang Qian Jiang Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia Haematologica |
| title | Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia |
| title_full | Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia |
| title_fullStr | Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia |
| title_full_unstemmed | Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia |
| title_short | Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia |
| title_sort | optimizing olverembatinib dose in chronic phase chronic myeloid leukemia |
| url | https://haematologica.org/article/view/12047 |
| work_keys_str_mv | AT xiaoshuaizhang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yunfanyang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT bingchengliu optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT xindu optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT xiaodongwang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT huanlingzhu optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT luyu optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT zongruli optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT shashazhao optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT linhuayang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yanpingma optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT limeng optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yanqingzhang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT guohuili optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT lijieyang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT baohongwang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT xuehongran optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT jianhuang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT nagao optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT qinwen optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yanwen optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yuxiazhao optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yuzhu optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yanqiuhan optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT zhenfangliu optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT xindu optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT jianyuweng optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT robertpetergale optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT lizhou optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT yanlizhang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia AT qianjiang optimizingolverembatinibdoseinchronicphasechronicmyeloidleukemia |